—Poster Presentation of Reverse Translational Study
Data Using Patient Samples Supports Role of CCL24 as a Therapeutic
Target for Systemic Sclerosis—
—Chemomab's CCL24-Neutralizing Antibody CM-101 Is Expected to
Enter a Phase 2 Trial in Systemic Sclerosis in Late 2022—
TEL
AVIV, Israel, June 2, 2022
/PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB)
(Chemomab), a clinical-stage biotechnology company focused on the
discovery and development of innovative therapeutics for fibrotic
and inflammatory diseases with high unmet need, today reported that
data supporting the role of CCL24 as a therapeutic target for
systemic sclerosis (SSc) is being presented in a poster at the
EULAR European Congress of Rheumatology this week.1
Chemomab's CCL24-neutralizing antibody, CM-101, is expected to
enter a Phase 2 trial in systemic sclerosis later this year.
The study, which was conducted in the laboratory of Professor
Francesco Del Galdo, Lead, Raynaud's
and Scleroderma Programme at Leeds University in the UK, examined
the role of CCL24 in longitudinal diffuse cutaneous systemic
sclerosis (dcSSc) patient cohorts by correlating serum levels of
CCL24 to disease activity markers and disease progression. The
findings support the role of CCL24 as a potential therapeutic
target, demonstrating elevated serum levels of CCL24 in patients
with dcSSc. High CCL24 serum levels were correlated with disease
activity and worse prognosis as reflected by high fibrotic activity
and deterioration of lung function over time.
Adi Mor, PhD, co-founder and
Chief Scientific Officer of Chemomab, commented, "We welcome the
opportunity to share the growing body of data confirming that CCL24
is a promising therapeutic target for systemic sclerosis at EULAR.
These data are timely and informative as we are now finalizing
plans for the upcoming Phase 2 trial of our CCL24-neutralizing
antibody, CM-101, in systemic sclerosis. We look forward to opening
clinical study sites in Europe and
the U.S. as the trial gets underway."
Study highlights included the following:
- dcSSc patients with positive anti-topoisomerase antibodies
(ATA) had higher levels of CCL24. ATA is a type of
anti-nuclear antibody seen in dcSSc patients that is correlated
with rapid disease progression.
- dcSSc patients who are ATA positive and have high CCL24
levels demonstrated higher ELF scores. The ELF (elevated
liver fibrosis) score is an independent, validated biomarker of
skin and lung involvement in SSc.
- Baseline CCL24 levels were positively associated with ELF
scores.
- Baseline CCL24 levels were correlated with lung disease
deterioration, measured by reduction of forced vital capacity
(FVC) after 12 months.
- High baseline CCL24 levels predicted worsening of lung
function (sub-analysis in patients that showed normal FVC at
baseline).
The authors conclude that the study data reinforces the
rationale for assessing the therapeutic utility of a
CCL24-neutralizing antibody in systemic sclerosis clinical
trials.
About Systemic Sclerosis
Systemic sclerosis, also known as scleroderma, is a rare
autoimmune rheumatic disease characterized by fibrosis and
inflammation of the skin, joints and internal organs, as well as
vascular abnormalities. It predominantly affects women and is
typically diagnosed when patients are between 30 and 50 years of
age. It is the most lethal of the systemic rheumatic diseases with
a median survival of only 10 years. There is no approved
disease modifying drug for the condition.
The poster is available via the EULAR 22 virtual conference
platform from June 1–July 31, 2022. It will also be available at
the R&D section of Chemomab's website after the conclusion of
the conference.
1 – "CCL24 serum concentration correlates with disease
activity and worse prognosis in diffuse cutaneous SSc: a promising
biological target to prevent disease
progression," M. Segal Salto, A. Mor,
F. Del Galdo, Poster: POS0489.
About Chemomab
Therapeutics
Chemomab is a clinical-stage biotechnology company focusing
on the discovery and development of innovative therapeutics for
fibrotic and inflammatory diseases with high unmet need. Based on
the unique and pivotal role of the soluble protein CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to bind and block CCL24 activity.
CM-101 has demonstrated the potential to treat multiple severe and
life-threatening fibrotic and inflammatory diseases. It is
currently in Phase 2 trials for primary sclerosing cholangitis and
liver fibrosis, with a Phase 2 trial in systemic sclerosis expected
to begin in late 2022. For more information,
visit chemomab.com.
Forward Looking
Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act. These
forward-looking statements include, among other things, statements
regarding the clinical development pathway for CM-101; the future
operations of Chemomab and its ability to successfully initiate and
complete clinical trials and achieve regulatory milestones; the
nature, strategy and focus of Chemomab; the development and
commercial potential and potential benefits of any product
candidates of Chemomab; and that the product candidates have the
potential to address high unmet needs of patients with serious
fibrosis-related diseases and conditions. Any statements contained
in this communication that are not statements of historical fact
may be deemed to be forward-looking statements. These
forward-looking statements are based upon Chemomab's current
expectations. Forward-looking statements involve risks and
uncertainties. Because such statements deal with future events and
are based on Chemomab's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of Chemomab could differ materially from those
described in or implied by the statements in this presentation,
including: risks related to Chemomab's ability to effectively
implement the revised clinical strategy and its ability to achieve
the anticipated results; risks related to the projections and
associated benefits in pursuing the contemplated changes to the
clinical strategy; risks associated with the ongoing transitions of
certain of our executive officers, including Chemomab's new Chief
Executive Officer; the uncertain and time-consuming regulatory
approval process; risks related to Chemomab's ability to correctly
manage its operating expenses and its expenses; Chemomab's plans to
develop and commercialize its product candidates, focusing on
CM-101; the timing of initiation of Chemomab's planned clinical
trials; the timing of the availability of data from Chemomab's
clinical trials including any potential delays associated with
Chemomab's contemplated revised clinical strategy; the timing of
any planned investigational new drug application or new drug
application; Chemomab's plans to research, develop and
commercialize its current and future product candidates; the
clinical utility, potential benefits and market acceptance of
Chemomab's product candidates; Chemomab's commercialization,
marketing and manufacturing capabilities and strategy; Chemomab's
ability to protect its intellectual property position; and the
requirement for additional capital to continue to advance these
product candidates, which may not be available on favorable terms
or at all. Additional risks and uncertainties relating to
Chemomab's and its business can be found under the caption "Risk
Factors" and elsewhere in Chemomab's filings and reports with the
SEC. Chemomab expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Chemomab's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based,
except to the extent required by applicable law.
Contacts:
Media:
Investor Relations:
Barbara Lindheim
Irina Koffler
Chemomab
Therapeutics
LifeSci Advisors, LLC
Consulting Vice President
Phone: +1-917-734-7387
Investor & Public Relations,
ir@chemomab.com
Strategic Communications
Phone: +1-917-355-9234
barbara@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/data-supporting-role-of-chemomabs-novel-therapeutic-target-ccl24-in-systemic-sclerosis-presented-at-eular-2022-301559894.html
SOURCE Chemomab Therapeutics, Ltd.